Rezolute completes enrollment in Phase 3 upLIFT trial of ersodetug

Rezolute Inc. announced that enrollment is complete for its open‑label Phase 3 upLIFT study of ersodetug in tumor‑induced hyperinsulinism, enrolling 16 participants. The company expects topline data in mid‑December 2026. Interim data showed seven of the first eight participants achieved the primary endpoint of at least a 50 % reduction in intravenous glucose use.

The upcoming topline results will determine whether Rezolute can move toward regulatory filing and potential commercialization, a key value driver for this clinical‑stage biotech. Analysts have set a $12.00 price target and a Buy rating, reflecting the market’s focus on the trial outcome.

  • 1Enrollment in the upLIFT study is now fully completed.
  • 2The trial includes approximately 16 participants with insulinoma or non‑islet cell tumors.
  • 3Topline results are expected in mid‑December 2026.
  • 4Seven of the first eight participants met the primary responder criterion of at least a 50 % reduction in glucose infusion rate.
  • 5Rezolute will continue its expanded access program for compassionate use of ersodetug.
  • 6Analyst rating is Buy with a $12.00 price target.
  • Market capitalization is reported as $409 million and $471.1 million.

Sources